Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Los Angeles Biomedical Research Institute Emmaus Medical, Inc. |
---|---|
Information provided by: | Los Angeles Biomedical Research Institute |
ClinicalTrials.gov Identifier: | NCT00586209 |
To primary purpose is to evaluate the effect of L-glutamine therapy on exercise endurance and breath by breath exercise response of sickle cell anemia patients
The secondary purpose is to assess the effect of L-glutamine on pain; energy and appetite levels; narcotics usage; and hospital and emergency room visits for sickle cell pain
Condition | Intervention | Phase |
---|---|---|
Sickle Cell Anemia Thalassemia |
Drug: L-Glutamine Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia |
Estimated Enrollment: | 50 |
Study Start Date: | January 2003 |
Estimated Study Completion Date: | January 2009 |
Estimated Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
L-glutamine group will be given at the following dosage: 17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily |
Drug: L-Glutamine
L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (>66.7 kg)
|
2: Placebo Comparator
Placebo group will be given at the following dosage: 17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily |
Drug: Placebo
Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
|
This is a phase II, prospective, randomized, double-blind, placebo-controlled, parallel-group,study to evaluate the safety and efficacy of oral L-glutamine therapy for patients with sickle cell anemia or sickle IS°-thalassemia who are at least 18 years old with focus on the aspect of exercise endurance. In this study, the patients will orally take L-glutamine or placebo twice daily, and clinical and hematological parameters will be monitored. The adverse events,especially those attributable to L-glutamine therapy, will also be monitored. The data obtained will be essential in understanding the role of L-glutamine in therapy for sickle cell anemia and sickle B°-thalassemia.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
To be eligible to participate in the study, a patient must meet all of the following inclusion criteria:
Exclusion Criteria:
If the patient meets any of the following criteria, the patient must not be enrolled:
United States, California | |
LA BIomed At Harbor UCLA Medical Center | |
Torrance, California, United States, 90502 | |
LA Biomed at Harbor-UCLA Medical Center | |
Torrance, California, United States, 90502 |
Principal Investigator: | Yutaka Niihara, MD | LaBiomed At Harbor-UCLA Medical Center |
Responsible Party: | LA Biomed at Harbor-UCLA Medical Center ( Yutaka Niihara, MD ) |
Study ID Numbers: | 10511-01RY |
Study First Received: | December 21, 2007 |
Last Updated: | October 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00586209 |
Health Authority: | United States: Food and Drug Administration |
sickle cell disease sickle cell anemia L-glutamine Sickle Cell Anemia (homozygous and heterozygous) Sickle ß0-Thalassemia |
Anemia, Hemolytic, Congenital Genetic Diseases, Inborn Hematologic Diseases Hemoglobinopathies Anemia |
Anemia, Hemolytic Hemoglobinopathy Thalassemia Anemia, Sickle Cell Sickle cell anemia |